Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Schillaci, Roxana ^a   Guzmán, Pablo ^b   Cayrol, Florencia ^a   Beguelin, Wendy ^a   Díaz Flaqué, María C ^a   Proietti, Cecilia J ^a   Pineda, Viviana ^c   Palazzi, Jorge ^d   Frahm, Isabel ^e   Charreau, Eduardo H ^a   Maronna, Esteban ^e   Roa, Juan C ^b   Elizalde, Patricia V ^a,f  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

^d UNIVERSIDAD ABIERTA INTERAMERICANA   (Argentina)

^e Sanatorio Mater Dei   (Argentina)

^f INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; STEROID RECEPTOR; TUMOR MARKER; MEMBRANE PROTEIN; NUCLEAR PROTEIN;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR VOLUME; AGED; BREAST TUMOR; CARCINOMA; CHEMISTRY; CHILE; KAPLAN MEIER METHOD; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CHILE; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84860513974     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-74     Document Type: Article

References (39)

1. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999, 274:17209-17218. 10.1074/jbc.274.24.17209, 10358079.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
4. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
5. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280. 10.1038/ncponc0509, 16683005.
6. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004, 6:251-261. 10.1016/j.ccr.2004.07.012, 15380516.
7. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M, Crotty TB, McDermott E, Hill AD, Young LS. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 2008, 15:745-753. 10.1677/ERC-08-0009, 18469157.
8. Beguelin W, Diaz Flaque MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 2010, 30:5456-5472. 10.1128/MCB.00012-10, 2976427, 20876300.
9. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004, 9:95-104.
10. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008, 630:189-205. 10.1007/978-0-387-78818-0_12, 18637492.
11. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636. 10.1200/JCO.2002.02.026, 12202663.
12. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let's do it. Am J Clin Pathol 1995, 103:123-124.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
14. Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007, 43:725-735. 10.1016/j.ejca.2006.11.019, 17251007.
15. Upton G. Fisher's exact test. Journal of the Royal Statistical Society, Series A 1992, 155:395-402.
16. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007, 165:710-718. 10.1093/aje/kwk052, 17182981.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
18. Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN, Gobbi H. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 2008, 61:934-938. 10.1136/jcp.2007.053892, 18474540.
19. Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Diaz Flaque MC, Charreau EH, Schillaci R, Elizalde PV. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 2009, 29:1249-1265. 10.1128/MCB.00853-08, 2643818, 19103753.
20. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009, 16:333-350. 10.1677/ERC-08-0244, 19190078.
21. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, Bartholomeusz G, Wang SC, Hung MC. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005, 25:11005-11018. 10.1128/MCB.25.24.11005-11018.2005, 1316946, 16314522.
22. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95:142-153. 10.1093/jnci/95.2.142, 12529347.
23. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
25. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
26. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
27. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005, 65:338-348.
28. Peredo R, Sastre G, Serrano J, Hunter MR. Her-2/neu oncogene expression in Puerto Rican females with breast cancer. Cell Mol Biol (Noisy-le-Grand) 2001, 47:1025-1032.
29. Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncol Rep 2007, 18:121-126.
30. Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM, Soares FA. Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 2010, 37:41-49.
31. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368. 10.1634/theoncologist.2008-0230, 19346299.
32. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998, 52:261-288. 10.1023/A:1006141703224, 10066087.
33. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
34. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440. 10.1016/j.ccr.2009.03.020, 19411071.
35. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nole F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699. 10.1200/JCO.2009.22.0962, 19884553.
36. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27:5700-5706. 10.1200/JCO.2009.23.2025, 2792998, 19884543.
37. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
38. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991, 63:434-438. 10.1038/bjc.1991.100, 1971853, 1672253.
39. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 2010, 28:963-968. 10.3109/07357907.2010.496759, 20690807.